Sign in

NCT06623305Not yet recruiting

A Clinical Trial of the Administration of Light Therapy to Prevent Mouth Sores in Children With Cancer

Photobiomodulation Therapy for the Prevention of Mucositis in Pediatric Oncology Patients

Source: ClinicalTrials.gov · Last updated 6 Oct 2026

Brief summary (registry, in English)

The goal of this clinical trial is to learn if light therapy can prevent mouth sores in children with cancer. The main questions it aims to answer are: Is it reasonable and acceptable to provide light therapy for children with cancer? Does light therapy prevent mouth sores related to medical treatment? Researchers will compare children who do not receive light therapy to children who do receive light therapy during the clinical trial to see if light therapy helps to prevent mucositis. Participants will: * Complete a survey. * Have picture taken of their mouth to look for mouth sores. * Receive light therapy every day while admitted to the hospital on the cancer unit or while admitted to an alternate unit, and continue to receive light therapy in the home setting until they reach 8 days after the start of their chemotherapy cycle.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
50 (estimated)
First submitted
27 Sept 2024
Start date
Nov 2026
Primary completion date
Nov 2027
Lead sponsor
Medical College of Wisconsin
NCT number
NCT06623305

What you commit to

  • Study type: Interventional
  • Planned participants: 50
  • From Nov 2026 to the primary completion date, Nov 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Patients admitted on BMT service
  • Patients currently experiencing mucositis with a CTCAE grade 4 oral mucositis or higher

Who the study is looking for

  • Current and new diagnosis patients consented upon admission if deemed eligible
  • Ages 0-30
  • Admitted to CW oncology/BMT inpatient unit, PICU, or West 5
  • Chemotherapy regimen: Methotrexate ≥5 g/m2 (or ≥1 g/m2 if Trisomy 21) OR Anthracycline ≥60 mg/m2
  • Able to speak and understand English or Spanish

Age in the registry: - to 30 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Medical College of Wisconsin
Coordinator of this site? Confirm its status
MilwaukeeUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.